The Cooley LLP capital markets practice advises issuers and underwriters across the full spectrum of equity offerings. The group, which is jointly led by Charlie Kim and David Peinsipp, brings particular strength with initial public offerings in the technology, healthcare and life sciences sectors. In San Francisco, Peinsipp excels in a broad range of sophisticated securities offerings including direct listings, follow-on offerings, Rule 144A transactions and private investments in public equity. In San Diego, Kim is a leading advisor on equity and debt issuances, with a strong focus on technology and consumer sector companies. In the New York office, Div Gupta is regularly retained by investment banks across industries and is well regarded for his work on initial public offerings of common stock. Fellow New York IPO specialist Richard Segal is highly active across the technology, consumer and retail sectors. In Chicago, Christina Roupas counsels public companies on disclosure obligations, corporate governance and compliance matters. Partner Jonie Kondracki departed the firm in October 2025.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Excellent team with huge experience in capital markets and great SEC recognition. Each partner works well with each other for a seamless process.’
‘Div Gupta is a great coordinator for the client. Very mature, open to solutions, fast to execute.’
‘We love working with Cooley. They are able to support us in solving the most complex of issues while simultaneously understanding the start-up pace at which we operate. The entire team is easy to work with, has deep subject matter expertise, and enables commercial problem solving.’
‘Christina Roupas and Courtney Tygesson operate in a way that has gained the support of not just our legal team, but our entire executive team. They are able to gain quick understanding of our business, and just as importantly, our culture. Able to understand key facets of any legal issue in order to provide guidance that enables effective problem-solving. Christina, Courtney and their entire team have become critical partners of our legal team. ’
‘Excellent team of experienced partners who are highly commercial, responsive and thoughtful. ’
‘Their advise is more practical and business minded than other large firms I have worked with. They are also very knowledgeable about the tech space and extremely responsive.’
Key clients
- Navan
- J.P. Morgan Securities
- LB Pharmaceuticals
- MapLight Therapeutics
- Beta Bionics
- Evommune
- Ambiq Micro
- BofA Securities
- J.P. Morgan Securities
- J.P. Morgan Securities
- Aardvark Therapeutics
- Morgan Stanley & Co.
Work highlights
Advised Navan on its $923 million IPO of Class A common stock. Navan offered 30,000,000 shares, and certain selling stockholders offered 6,924,406 shares, priced at $25 per share.
Advised the underwriters on Stubhub’s $800 million IPO of 34,042,553 shares of Class A common stock priced at $23.50 per share.
Advised Beta Bionics on its $234.6 million IPO of 13,800,000 shares of common stock at a public offering price of $17.00 per share.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Charlie Kim
David Peinsipp
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Richard Segal
Practice head
Charlie Kim; David Peinsipp
Other key lawyers
Div Gupta; Christina Roupas; Courtney Tygesson; Richard Segal